Advertisement

Adalimumab Superior to Placebo for Patient-Reported Outcomes in PsA

An analysis of the randomized, controlled ADEPT trial was presented at the ACR/ARP Annual Meeting and demonstrated adalimumab’s superiority to placebo among patients with...

Congenital Heart Block Risk with Hydroxychloroquine in Pregnant Patients with SLE

A recent trial evaluated the effect of hydroxychloroquine (HCQ) on the recurrence of congenital heart block (CHB) in pregnant patients with systemic lupus erythematosus...

Tildrakizumab Versus Placebo in Active PsA

A study presented at the ACR/ARP Annual Meeting detailed 24-week outcomes among patients with active psoriatic arthritis (PsA) treated with tildrakizumab compared with placebo....

The Relationship Between axSpA and Psoriasis

An estimated 10% of patients with axial spondyloarthritis (axSpA) also present with psoriasis. While it is believed that a phenotype of the disease is...
Advertisement